Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Director | June 17, 2026 | June 18, 2026 |
| Oric Pharmaceuticals, Inc.ORIC · Entity 4765 | Director · PRESIDENT AND CEO | January 02, 2026 | January 06, 2026 |
| Turning Point Therapeutics, Inc.TPTX · Entity 124461 | Director | June 15, 2020 | June 17, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.42 · Expires 2036-06-16 | Direct | 50,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 50,000 · Balance 50,000 F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).
Oric Pharmaceuticals, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.17 · Expires 2036-01-01 | Direct | 675,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 675,000 · Balance 675,000 F1: 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 112,500 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 112,500 · Balance 112,500 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.
F3: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028.
Turning Point Therapeutics, Inc.
Report date June 15, 2020 · Filed June 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.39 · Expires 2030-06-14 | Direct | 8,500 |
Reported balance
After 2020-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-15 · Grant · Acquired 8,500 · Balance 8,500 F1: The shares vest on the one-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the one-year anniversary of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ignyta, Inc.
Report date February 08, 2018 · Filed February 12, 2018
Section 16 reporting ended · disclosed 2018-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 1
1 source rowRow 1 · 2018-02-08 · Disposition to issuer · Disposed 70,572 · Balance 0 F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.40 · Expires 2024-05-29 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-08 · Disposition to issuer · Disposed 250,000 · Balance 0 F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.58 · Expires 2025-01-07 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-08 · Disposition to issuer · Disposed 25,200 · Balance 0 F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2027-01-04 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-08 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger").
F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2022 Filed May 25, 2022 23:00 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001567619-22-011718 · doc1.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2032-05-22 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2023 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2025. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| May 13, 2022 Filed May 13, 2022 22:52 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | PurchaseCommon Stock | 76,072 | $2.82 | $214,561.08 |
DisclosureSEC source: 0001209191-22-028963 · doc4.xml · nonDerivative · entry 3 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 802,652 F3 · price: Represents the weighted average share price of an aggregate total of 76,072 shares purchased in the price range of $2.79 to $2.93 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 12, 2022 Filed May 13, 2022 22:52 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | PurchaseCommon Stock | 69,354 | $2.75 | $190,466.89 |
DisclosureSEC source: 0001209191-22-028963 · doc4.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 726,580 F2 · price: Represents the weighted average share price of an aggregate total of 69,354 shares purchased in the price range of $2.70 to $2.77 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 11, 2022 Filed May 13, 2022 22:52 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | PurchaseCommon Stock | 304,574 | $2.90 | $883,569.17 |
DisclosureSEC source: 0001209191-22-028963 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 657,226 F1 · price: Represents the weighted average share price of an aggregate total of 304,574 shares purchased in the price range of $2.695 to $2.95 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 25, 2022 Filed Mar 25, 2022 22:42 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | PurchaseCommon Stock | 50,000 | $4.54 | $227,170.00 |
DisclosureSEC source: 0001209191-22-021153 · doc4.xml · nonDerivative · entry 3 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,652 F3 · price: Represents the weighted average share price of an aggregate total of 50,000 shares purchased in the price range of $4.455 to $4.60 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 24, 2022 Filed Mar 25, 2022 22:42 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | PurchaseCommon Stock | 42,873 | $5.03 | $215,659.76 |
DisclosureSEC source: 0001209191-22-021153 · doc4.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,652 F2 · price: Represents the weighted average share price of an aggregate total of 42,873 shares purchased in the price range of $5.03 to $5.05 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 22:42 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | PurchaseCommon Stock | 257,127 | $4.98 | $1,280,878.15 |
DisclosureSEC source: 0001209191-22-021153 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,779 F1 · price: Represents the weighted average share price of an aggregate total of 257,127 shares purchased in the price range of $4.73 to $5.10 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:04 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantRestricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006336 · doc4.xml · derivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. F3 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:04 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $9.48 | $0.00 |
DisclosureSEC source: 0001209191-22-006336 · doc4.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 1, 2023, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 22:17 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 3,736 | $25.06 | $93,628.64 |
DisclosureSEC source: 0001209191-21-056460 · doc4.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,652 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average share price of an aggregate total of 3,736 shares sold in the price range of $25.00 to $25.25 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 22:17 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 4,420 | $25.05 | $110,706.41 |
DisclosureSEC source: 0001209191-21-056460 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,388 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 4,420 shares sold in the price range of $25.00 to $25.22 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 20:01 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 2,801 | $25.02 | $70,088.86 |
DisclosureSEC source: 0001209191-21-055866 · doc4.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,808 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average share price of an aggregate total of 2,801 shares sold in the price range of $25.00 to $25.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:01 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 2,942 | $25.08 | $73,783.30 |
DisclosureSEC source: 0001209191-21-055866 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,609 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 2,942 shares sold in the price range of $25.00 to $25.28 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 20:33 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 200 | $25.04 | $5,007.00 |
DisclosureSEC source: 0001209191-21-055291 · doc4.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,551 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average share price of an aggregate total of 200 shares sold in the price range of $25.00 to $25.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:33 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 5,981 | $25.11 | $150,173.34 |
DisclosureSEC source: 0001209191-21-055291 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,751 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 5,981 shares sold in the price range of $25.00 to $25.295 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 27, 2021 Filed May 28, 2021 23:36 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 400 | $25.07 | $10,028.00 |
DisclosureSEC source: 0001209191-21-036686 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,732 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 400 shares sold in the price range of $25.00 to $25.10 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 24, 2021 Filed May 24, 2021 23:27 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 12 | $25.00 | $300.00 |
DisclosureSEC source: 0001209191-21-035523 · doc4.xml · nonDerivative · entry 3 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,132 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 21, 2021 Filed May 24, 2021 23:27 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 4,790 | $25.20 | $120,687.88 |
DisclosureSEC source: 0001209191-21-035523 · doc4.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,144 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average share price of an aggregate total of 4,790 shares sold in the price range of $25.00 to $25.37 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 20, 2021 Filed May 24, 2021 23:27 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 2,468 | $25.07 | $61,863.88 |
DisclosureSEC source: 0001209191-21-035523 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,934 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 2,468 shares sold in the price range of $25.00 to $25.14 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 18, 2021 Filed May 19, 2021 00:17 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 200 | $26.03 | $5,206.00 |
DisclosureSEC source: 0001209191-21-033813 · doc4.xml · nonDerivative · entry 4 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,402 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 18, 2021 Filed May 19, 2021 00:17 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 11,132 | $25.37 | $282,427.75 |
DisclosureSEC source: 0001209191-21-033813 · doc4.xml · nonDerivative · entry 3 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,602 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 11,132 shares sold in the price range of $25.00 to $25.93 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2021 Filed May 19, 2021 00:17 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 2,550 | $25.05 | $63,884.13 |
DisclosureSEC source: 0001209191-21-033813 · doc4.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,734 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average share price of an aggregate total of 2,550 shares sold in the price range of $25.00 to $25.27 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2021 Filed May 20, 2021 00:33 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001567619-21-010749 · doc1.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2031-05-16 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 17, 2022 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 17, 2024. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| May 14, 2021 Filed May 19, 2021 00:17 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 13,896 | $25.36 | $352,465.09 |
DisclosureSEC source: 0001209191-21-033813 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,284 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 13,896 shares sold in the price range of $25.00 to $25.85 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 13, 2021 Filed May 13, 2021 23:57 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 730 | $25.04 | $18,281.03 |
DisclosureSEC source: 0001209191-21-032508 · doc4.xml · nonDerivative · entry 3 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,180 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 730 shares sold in the price range of $25.00 to $25.26 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 12, 2021 Filed May 13, 2021 23:57 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 400 | $25.02 | $10,009.60 |
DisclosureSEC source: 0001209191-21-032508 · doc4.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,910 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average share price of an aggregate total of 400 shares sold in the price range of $25.00 to $25.04 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 11, 2021 Filed May 13, 2021 23:57 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 1,090 | $25.22 | $27,489.58 |
DisclosureSEC source: 0001209191-21-032508 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,310 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 1,090 shares sold in the price range of $25.16 to $25.32 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 30, 2021 Filed Apr 30, 2021 23:56 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 600 | $25.24 | $15,142.98 |
DisclosureSEC source: 0001209191-21-029375 · doc4.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,400 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average share price of an aggregate total of 600 shares sold in the price range of $25.10 to $25.44 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 23:56 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 700 | $25.06 | $17,541.72 |
DisclosureSEC source: 0001209191-21-029375 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,000 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 700 shares sold in the price range of $25.00 to $25.12 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 23:40 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 800 | $25.09 | $20,069.60 |
DisclosureSEC source: 0001209191-21-025492 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,700 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 800 shares sold in the price range of $25.00 to $25.22 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 00:29 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 280,000 | $0.00 Strike: $29.83 | $0.00 |
DisclosureSEC source: 0001209191-21-006962 · doc4.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2031-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 1, 2022, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 23:02 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantStock Option (right to buy) · Derivative | 8,500 | $0.00 Strike: $65.39 | $0.00 |
DisclosureSEC source: 0001209191-20-037414 · doc4.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2030-06-14 F1 · derivative.exercise_date: The shares vest on the one-year anniversary of the date of grant. Read SEC document |
| April 28, 2020 Filed Apr 28, 2020 21:06 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | ConversionSeries C Preferred Stock · Derivative | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025981 · doc4.xml · derivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.exercise_date: The Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. Read SEC document |
| April 28, 2020 Filed Apr 28, 2020 21:06 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | ConversionCommon Stock | 62,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-025981 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 20:37 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 437,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025801 · doc4.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,500 Underlying: Common Stock · 437,500 shares Expires 2030-04-22 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on April 23, 2021, and 1/48 of the shares subject to the option shall vest each month thereafter. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 22:02 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $27.06 | $0.00 |
DisclosureSEC source: 0001209191-19-025788 · doc4.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-04-21 F1 · derivative.exercise_date: The option will become fully vested on the date of the Issuer's 2020 annual meeting of stockholders. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:28 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-18-009139 · doc4.xml · derivative · entry 4 Chacko Jacob · CIK 0001608936 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2027-01-04 F2 · derivative.exercise_date: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:28 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,200 | $0.00 Strike: $6.58 | $0.00 |
DisclosureSEC source: 0001209191-18-009139 · doc4.xml · derivative · entry 3 Chacko Jacob · CIK 0001608936 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,200 shares Expires 2025-01-07 F2 · derivative.exercise_date: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:28 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $7.40 | $0.00 |
DisclosureSEC source: 0001209191-18-009139 · doc4.xml · derivative · entry 2 Chacko Jacob · CIK 0001608936 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2024-05-29 F2 · derivative.exercise_date: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:28 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerCommon Stock | 70,572 | $27.00 | $1,905,444.00 |
DisclosureSEC source: 0001209191-18-009139 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). Read SEC document |
| January 05, 2018 Filed Jan 6, 2018 01:09 UTC | Ignyta, Inc. RXDX · Entity 169521 | GrantCommon Stock | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-002592 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,572 F1 · shares: Represents the grant of restricted stock units to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units will vest as to 25% of the shares underlying each award on each anniversary of the Grant Date, subject to the Reporting Person's continues service with the Company through the vesting date. Read SEC document |
| December 22, 2017 Filed Dec 23, 2017 02:44 UTC | Ignyta, Inc. RXDX · Entity 169521 | GrantCommon Stock | 23,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067159 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,172 F1 · shares: Represents the grant of restricted stock units to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units will vest as to 25% of the shares underlying each award on each anniversary of the Grant Date, subject to the Reporting Person's continues service with the Company through the vesting date. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 23:45 UTC | Ignyta, Inc. RXDX · Entity 169521 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-17-002761 · doc4.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-01-04 F1 · derivative.exercise_date: The option is exercisable as it vests. 25% of the shares subject to the option vest on January 5, 2018, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.